News

Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma

15 October 2019 SYDNEY, AUSTRALIA – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announces mature positive efficacy data from its TACTI-mel Phase…

Tim Oldham Appointed as Chief Executive Officer of AdAlta Ltd

9.10.2019 MELBOURNE Australia: The Board of AdAlta Limited (ASX:1AD), is pleased to announce the appointment of experienced global pharmaceutical executive Dr Tim Oldham as Chief Executive Officer and Managing Director. Dr Oldham has extensive skills and expertise over…

Smileyscope secures a prominent Silicon Valley investor

9 October 2019 August and September have been landmark months for Smileyscope.  We welcome our largest investor to date, and are closing a funding round which will allow us to grow rapidly through the next 18 months.  Our…

Opthea To Present at the Ophthalmology Innovation Summit in San Francisco

4 October 2019 Melbourne, Australia – Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, announced today that Dr Megan Baldwin, the Company’s Chief Executive Officer, will present at the Ophthalmology Innovation…

Cartherics Pty Ltd to Present at 2019 Cell & Gene Meeting on the Mesa

1 October 2019 Melbourne, Australia, – Cartherics Pty Ltd announced today that Professor Richard Boyd, Chief Scientific Officer, will present at the annual Cell & Gene Meeting on the Mesa to be held October 2-4 in Carlsbad, California.…

Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data

26 September 2019 • Requisite clinical responses achieved in cohort 1 of Part A (1st line NSCLC) of TACTI-002 Phase II clinical trial to allow for recruitment of cohort 2 • Recruitment of cohort 2 of Part A…

Opthea Receives A$14.6m R&D Tax Incentive

1 October, 2019 Melbourne, Australia – Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing novel biologic therapies to treat back-of-the-eye diseases, announced today it received a A$14.6 million research and development (R&D) tax credit from the Australian Taxation…

Medical Device Partnering Program (MDPP Victoria) drop-in sessions

11 September 2019 Calling all Victorian-based stakeholders! Keep an eye out as the Medical Device Partnering Program (MDPP) will be in your neighbourhood! Drop-In sessions will run for the next few weeks as part of our ongoing strategy to…

Collaboration Agreement signed between GTG and The Translational Genomics Research Institute (TGen) of Phoenix, Arizona USA

24 September 2019 Genetic Technologies Limited (“Company”), a provider of world-leading genetic risk assessment test products today announced that it has signed a 3-year Collaboration Agreement with TGen. TGen, an affiliate of City of Hope in Duarte, California,…

Pharmaceutical and Medtech Export Growth Soars

23 September 2019 Minister for Jobs, Innovation and Trade Victoria’s medtech and pharmaceutical sector is booming, with new data released today showing that support from the Andrews Labor Government has fuelled exceptional export growth. A report by ACIL…

Immutep to receive £4M milestone payment from GSK

23 September 2019 Sydney, Australia – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces that it will receive a milestone payment from GSK…

The PoC (Point of Care) is not where it used to be…

19 September In the US, the shift in where care is rendered is practically seismic. Almost overnight it seems (5 years in real world terms), retail clinics have become an important part of primary care and convenience is…

Home

News & opinion

Member Directory

Events